Chemomab Therapeutics (CMMB) vs CytoMed Therapeutics (GDTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CytoMed Therapeutics (GDTC) has outperformed Chemomab Therapeutics (CMMB) over the past year, losing 56.5% versus a loss of 60.3%. CytoMed Therapeutics is the larger company by market cap ($11.3 million vs $10.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMMB | GDTC |
|---|---|---|
| Share price | $1.39 | $0.9449 |
| Market cap | $10.19M | $11.28M |
| 1-day change | +2.21% | -3.56% |
| YTD return | -15.76% | -29.22% |
| 1-year return | -60.29% | -56.46% |
| 5-year return | -96.18% | — |
| EPS (TTM) | $-1.04 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.55 | $3.68 |
| 52-week low | $1.05 | $0.68 |
| Distance from 52-week high | -60.85% | -74.32% |
| Analyst consensus | none | none |
| Avg. price target upside | +259.71% | +340.26% |
| Average volume | 118.53K | 78.41K |
| Shares outstanding | 7.33M | 11.93M |
| Employees | — | 42 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Chemomab Therapeutics
CMMB stock →Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Healthcare · Biotechnology
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Healthcare · Biotechnology · 42 employees
CMMB vs GDTC FAQ
Which is bigger, Chemomab Therapeutics or CytoMed Therapeutics?
CytoMed Therapeutics (GDTC) is larger, with a market capitalization of $11.28M compared with $10.19M for Chemomab Therapeutics (CMMB).
Which stock has performed better over the past year, CMMB or GDTC?
GDTC returned -56.46% over the past 12 months, compared with -60.29% for CMMB (price return, excluding dividends). Past performance does not predict future results.
Are Chemomab Therapeutics and CytoMed Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.